Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials69
Emerging therapeutics in Huntington’s disease25
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder22
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?18
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia18
New drugs targeting calcitonin gene-related peptide for the management of migraines15
A review of phase II and III drugs for the treatment and management of endometriosis15
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review13
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials13
Emerging drugs for the treatment of postsurgical pain13
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?12
Emerging medicines to improve the basic defect in cystic fibrosis12
Emerging biological treatments for asthma11
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials11
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Emerging injectable therapies for osteoarthritis11
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia9
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms9
Cannabinoid treatment for the symptoms of autism spectrum disorder8
Emerging drugs for the treatment of herpetic keratitis8
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder7
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials7
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria7
A review of emerging factor XI inhibitors7
Expert opinion on emerging drugs for lung chronic graft-versus-host disease7
Emerging antiviral therapies and drugs for the treatment of influenza6
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?6
Emerging tyrosine kinase inhibitors for head and neck cancer6
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma6
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials6
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma6
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Correction5
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials5
Emerging therapies for dry eye disease5
How will tovorafenib change our treatment of pediatric low-grade glioma?5
Emerging drugs for the treatment of irritability associated with autism spectrum disorder5
Recent advances in immune-based approaches for the treatment of esophagogastric cancer5
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis5
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis5
0.092280864715576